George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFrontier Ip Regulatory News (FIPP)

Share Price Information for Frontier Ip (FIPP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 41.50
Bid: 41.00
Ask: 42.00
Change: -2.00 (-4.60%)
Spread: 1.00 (2.439%)
Open: 43.50
High: 43.50
Low: 41.50
Prev. Close: 43.50
FIPP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Second Portuguese spin out: Des Solutio

30 Oct 2018 07:00

RNS Number : 5786F
Frontier IP Group plc
30 October 2018
 

30 October 2018

 

Frontier IP Group Plc

("Frontier IP" or the "Group")

 

 

Portfolio news - Second Portuguese spin out Des Solutio to develop green chemistry for beauty, pharmaceutical and food industries

 

Frontier IP, a specialist in commercialising university intellectual property, today announces it is taking a 25 per cent. stake in Des Solutio (the "Company"), a company developing safer and greener alternatives to the chemicals currently used to make beauty, pharmaceutical, personal care and other products.

 

The Company has been established to develop and commercialise the research of Associate Professor Ana Rita Duarte and Dr Alexandre Paiva, of Portugal's NOVA University Lisbon, NOVA School of Science and Technology ("FCT NOVA").

 

Their research has already attracted interest from several major industrial groups, including a world-leading cosmetics company and a major pharmaceutical company. In return for its stake, Frontier IP will provide Des Solutio with a broad range of commercialisation services, including contract negotiation and identifying and working with potential industry partners to validate and scale up the technology.

 

Des Solutio is developing new methods to use Natural Deep Eutectic Solvents ("NADES") in cosmetics, nutraceuticals and other applications, to replace toxic organic solvents, such as ethanol, employed currently. Solvents are commonly used in a wide range of industries to extract active ingredients from natural matrices, such as olive oil, mint or seaweed to flavour and scent their products, and enhance the shelf-life and stability of the bioactives.

 

NADES offer many benefits over existing solvents. Found in a vast range of plants, and so compliant with a green chemistry philosophy, they are entirely derived from natural compounds such as organic acids, amino acids and sugars.

 

As there are a vast range of NADES already identified, they can be matched to specific active ingredients to extract only what is needed. There is no need to recover an active ingredient from a NADES, unlike conventional solvents, some of which are too toxic for use on skin or in foods.

 

Other advantages of the technology include improved solubility, permeability and bioavailability of the active compounds, better biodegradability than many organic solvents and greener production processes.

 

The incorporation of Des Solutio is a further sign of Frontier IP's growing momentum in Portugal. It is the Group's second spin out from FCT NOVA following NTPE, a company developing novel technology to print electronic circuits, sensors and semiconductors on to paper. The Group recently entered into a strategic partnership with the UK government's Department for International Trade in Portugal.

 

Des Solutio co-founder, Associate Professor Ana Rita Duarte said:  "We're delighted to be working with Frontier IP on developing and bringing this ground-breaking science into the commercial world. NADES have huge potential for making a host of everyday products greener and saferfor people to use."

 

Frontier IP chief executive Neil Crabb said: "We're very excited about the possibilities for Des Solutio. The technology being developed by Professor Ana Rita Duarte and Dr Alexandre Paiva has already attracted interest from major multinationals. Its incorporation as our second Portuguese spin out is further sign of our growing strength in the country."

 

 

ENQUIRIES

 

Frontier IP Group Plc

T: 0131 240 1251

Neil Crabb, Chief Executive

Andrew Johnson, Communications & Investor Relations

Company website: www.frontierip.co.uk

 

M: 07464 546 025

Allenby Capital Limited (Nominated Adviser and Broker)

T: 0203 328 5656

Nick Athanas / Nicholas Chambers (Corporate Finance)

Amrit Nahal (Equity Sales)

 

NOTES TO EDITORS

Frontier IP unites science and commerce by identifying strong intellectual property and accelerating its development through a range of commercialisation services.

The Group looks to build and grow a portfolio of equity stakes and licence income by taking an active involvement in spin-out companies, including support for fund raising and collaboration with relevant industry partners at an early stage of development.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NRABLBDGBGDBGIC
Date   Source Headline
4th Dec 201912:00 pmRNSResult of AGM & Total Voting Rights
26th Nov 201912:58 pmRNSHolding(s) in Company
13th Nov 20195:00 pmRNSPosting of Annual Report and Accounts
7th Nov 201912:20 pmRNSHolding(s) in Company
6th Nov 20192:00 pmRNSResult of Placing
6th Nov 20197:01 amRNSProposed fundraising of £3.5m by way of Placing
6th Nov 20197:00 amRNSFinal Results
22nd Oct 20197:00 amRNSAppointment of senior advisers
15th Oct 20197:00 amRNSNew portfolio company: Elute Intelligence Holdings
10th Sep 20197:00 amRNSAppointment of Broker
25th Jul 20197:00 amRNSExscientia collaboration with Rallybio
15th Jul 201912:08 pmRNSHolding(s) in Company
14th Jun 20197:00 amRNSExscientia partnership with GT Apeiron
31st May 20195:00 pmRNSTotal Voting Rights
31st May 20193:15 pmRNSDirectorate Change
28th May 20197:00 amRNSFieldwork Robotics completes initial field trials
15th May 20197:00 amRNSDirector exercise of options, shareholding and TVR
10th May 201911:48 amRNSHolding(s) in Company
30th Apr 20197:00 amRNSEuropean plan to boost marine & coastal economies
8th Apr 20197:00 amRNSInvestor event at the Royal Academy of Engineering
8th Apr 20197:00 amRNSBosch UK to work with Pulsiv Solar
8th Apr 20197:00 amRNSParkside Architectural Tiles launch Alusid range
4th Apr 20197:00 amRNSExscientia reaches first major milestone with GSK
3rd Apr 20195:51 pmRNSHolding(s) in Company
3rd Apr 20193:45 pmRNSHolding(s) in Company
1st Apr 20197:00 amRNSFieldwork Robotics wins Innovate UK ISCF grant
27th Mar 20191:30 pmRNSHolding(s) in Company
27th Mar 20191:30 pmRNSHolding(s) in Company
27th Mar 20197:00 amRNSBoard Appointment
27th Mar 20197:00 amRNSUnaudited Half Year Results
21st Mar 20199:18 amRNSTrading Update
21st Mar 20199:14 amRNSExscientia & Celgene drug discovery collaboration
6th Mar 20195:15 pmRNSHolding(s) in Company
20th Feb 20197:00 amRNSTVG - key partner in $9.67m DARPA project award
12th Feb 20197:00 amRNSThird Portuguese spin out: Insignals Neurotech
4th Feb 20197:00 amRNSAmprologix wins DHSC backing for new antibiotic
31st Jan 20199:00 amRNSNandi Proteins led consortium wins UK grant
25th Jan 20197:00 amRNSThe Vaccine Group wins Department of Health grant
7th Jan 20191:29 pmRNSExscientia Series B funding & Roche collaboration
27th Dec 20187:00 amRNSMolendotech - Palintest start commercial roll out
19th Dec 201811:45 amRNSResult of AGM
30th Nov 20185:30 pmRNSTotal Voting Rights
23rd Nov 201812:10 pmRNSPosting of Annual Report and Notice of AGM
22nd Nov 20181:12 pmRNSHolding(s) in Company
22nd Nov 201810:36 amRNSHolding(s) in Company
21st Nov 20183:30 pmRNSHolding(s) in Company
21st Nov 201811:00 amRNSTotal Voting Rights and Director/PDMR Shareholding
15th Nov 20184:08 pmRNSDirector Dealing
15th Nov 201812:37 pmRNSGrant of Options
15th Nov 201810:05 amRNSExscientia acquires Kinetic Discovery

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.